Search Results - tetsuya+takagawa

1 Results Sort By:
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Use of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing...
Published: 10/28/2024   |   Inventor(s): Tetsuya Takagawa, Atsushi Kitani, Warren Strober
Keywords(s): COLITIS, Crohn's, Disease, IB3XXX, inhibitor, LRRK2, TREAT, Ulcerative, VPXXXX, WKXXXX, XEXXXX, YAXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Endocrinology, TherapeuticArea > Infectious Disease, TherapeuticArea > Dental, TherapeuticArea > Ophthalmology, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Cardiology